As we move into our next phase of growth, I’m pleased to share a number of key updates.

All key development and licensing approvals have now been secured for IsoMedica, clearing the way for construction of the entX Advanced Radioisotope Manufacturing Facility (ARMF) to commence in March. Orders for all long-lead capital items have been placed, positioning us for installation and commissioning in July, with first production targeted for Q4. This milestone reflects the disciplined execution of our strategy and the strong foundations we have built across engineering, regulatory and operational planning.

We continue to advance on engineering optimisation to support rapid scale-up from laboratory capability to full manufacturing operations, while progressing commissioning activities at the ARMF and Space Defence Manufacturing at Greenfields. The team draws upon decades of similar experience from adjacent industries to drive successful execution of this next phase of early commercialisation. Further on IsoMedica, we are finalising waste material offtake agreements with global mining partners to strengthen long-term feedstock security.

In Space and Defence, we are wrapping up our CRC-P and Moon to Mars Trailblazer programs, both with successful outcomes. Our RHU Flight Heritage launch in New Mexico remains on track for later this year. This will pave the way for ongoing work with the likes of iSpace and Fleet Space, with a focus on systems integration to enable lunar night survival capability of their respective technologies, scheduled for various launches later this decade.

Together, these developments reinforce our commitment to building a resilient, vertically integrated capability and delivering sustainable value for our stakeholders.

We will also be hosting the first session of our upcoming webinar series on 19 March.  Register online.

Warm regards,

Bryn Jones 

Managing Director